2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (2ÀÏÂ÷) : 2022-10-16±³À°ÀÏÀÚ : 2022-10-16
±³À°Àå¼Ò : ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï ÄÚ¿¢½º Çϸð´Ïº¼·ë ¿Ü
±³À°ÁÖÁ¦ :
2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284
À̸ÞÀÏ :
kda@derma.or.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 26 ½Ã°£ 17ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í Á¤È¸¿ø 80,000 / ÁØȸ¿ø 40,000 / ºñȸ¿ø 500,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-16 Harmony 1+2 08:00~08:03 1. Introduction Chair()
±³À°½Ã°£ 10-16 Harmony 1+2 08:03~08:48 2. The importance of targeting type 2 inflammation in atopic dermatitis with dupilumab Àå¿ëÇö(°æºÏÀÇ´ë)
Åä·Ð 10-16 Harmony 1+2 08:48~09:00 3. Q&A ()
±³À°½Ã°£ 10-16 Harmony 1+2 09:00~09:50 1. Drug reactions associated with new chemotherapeutic agents Á¶¼ºÁø(¼¿ïÀÇ´ë)
Åä·Ð 10-16 Harmony 1+2 09:50~10:00 2. Q&A ()
±³À°½Ã°£ 10-16 Harmony 1+2 10:00~10:50 1. Social contract model for ethical deliberation of healthcare institutes ÀÌÀÏÇÐ(¿¬¼¼ÀÇ´ë À±¸®¹ýÀÇ·áÇаú)
Åä·Ð 10-16 Harmony 1+2 10:50~11:00 2. Q&A ()
±âŸ 10-16 Harmony 3 09:00~09:05 1. Overview Chair()
±³À°½Ã°£ 10-16 Harmony 3 09:05~09:20 2. Cutaneous scar: Basics and crucial determinants for a potentially scarless wound healing ±èÇý¼º(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 09:20~09:35 3. A review of hypertrophic scars and keloid and its treatment À¯ÈÁ¤(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 09:35~09:50 4. A review of atrophic scars and its treatment ÃÖõÇÊ(ÇϴôÀ³¦ÇǺΰú)
Åä·Ð 10-16 Harmony 3 09:50~10:00 5. Q&A ()
±âŸ 10-16 Harmony 3 12:30~12:35 1. Overview ³ë³«°æ(¸®´õ½ºÇǺΰú)
±³À°½Ã°£ 10-16 Harmony 3 12:35~12:50 2. Scars of different types and their key pathophysiology ³ë¹Ì·É(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 12:50~13:05 3. Prevention and early intervention of post-surgical scars ÃÖ¿µÁØ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 13:05~13:20 4. Combined surgical and nonsurgical treatment of old white scars ±¸º»Ã¶(³ªÀ½ÇǺΰú)
Åä·Ð 10-16 Harmony 3 13:20~13:30 5. Discussion, Q&A ()
±âŸ 10-16 Harmony 3 13:30~13:32 1. Overview Chair()
±³À°½Ã°£ 10-16 Harmony 3 13:32~13:44 2-1. Importance of bystanders such as keratinocyte and fibroblast in vitiligo pathogenesis À̽ÃÇü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 13:44~13:56 2-2. Insights into vitiligo pathogenesis utilized to create new targeted treatment strategies Á¤±âÇå(°æÈñÀÇ´ë)
Åä·Ð 10-16 Harmony 3 13:56~14:01 2-3. Q&A ()
±³À°½Ã°£ 10-16 Harmony 3 14:01~14:07 3-1. Case presentation (3 cases) À̱ټö À¯ÈÁ¤ ³ªÁ¤ÀÓ(¿ìÅÂÇÏÇѽ°æÇǺΰú °í·ÁÀÇ´ë ¼¿ïÀÇ´ë)
Åä·Ð 10-16 Harmony 3 14:07~14:30 3-2. Panel Discussion and Q&A À̱ټö À¯ÈÁ¤ ³ªÁ¤ÀÓ(¿ìÅÂÇÏÇѽ°æÇǺΰú °í·ÁÀÇ´ë ¼¿ïÀÇ´ë)
±âŸ 10-16 Harmony 3 15:00~15:05 1. Overview Chair()
±³À°½Ã°£ 10-16 Harmony 3 15:05~15:20 2. Occupational contact dermatitis - diagnosis, causes, and the importance of patch test ¹æöȯ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 15:20~15:35 3. Contact dermatitis related to hobbies - diagnosis, causes, and the importance of patch test Áֹμ÷(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 15:35~15:50 4. APEODS 2022 meeting report - update on contact dermatitis ÀÌ»óÀº(¿¬¼¼ÀÇ´ë)
Åä·Ð 10-16 Harmony 3 15:50~16:00 5. Q&A ()
±âŸ 10-16 Harmony 3 16:00~16:05 1. Overview Chair()
±³À°½Ã°£ 10-16 Harmony 3 16:05~16:20 2. The biggest and popular prescribed antibiotic for acne, doxycycline vs. minocycline ÀÌÈñÁ¤(Â÷ÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 16:20~16:35 3. Next generation of tetracyclines and other promising new agents ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 16:35~16:50 4. Retinoid and anti-androgens for acne treatment ÃÖÀ¯¼º(¼øõÇâÀÇ´ë)
Åä·Ð 10-16 Harmony 3 16:50~17:00 5. Q&A ()
±³À°½Ã°£ 10-16 Harmony 3 10:00~10:17 1. Allergic contact dermatitis (patch test) °íÁÖ¿¬(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 10:17~10:34 2. Genetic skin diseases (IIF mapping, NGS) ÀÌ»óÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 3 10:34~10:51 3. Autoimmune bullous diseases (IIF, ELISA) ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)
Åä·Ð 10-16 Harmony 3 10:51~11:00 4. Q&A ()
±³À°½Ã°£ 10-16 Vivace 08:30~08:44 1. History and overview ±è¹®¹ü(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 08:44~09:02 2. Devices: Classic D vs. polarized D ÀÌ°©¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 09:02~09:20 3. Nail disorder À̵¿À±(¼º±Õ°üÀÇ´ë)
Åä·Ð 10-16 Vivace 09:20~09:25 4. Q&A ()
±³À°½Ã°£ 10-16 Vivace 09:25~09:43 5. Melanocytic skin lesions vs. Melanoma ¹®Á¦È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 09:43~10:01 6. Precancerous lesions - Bowen, Actinic keratosis, etc. Àå¹Î¼ö(°í½ÅÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 10:01~10:19 7. NMSC - Basal cell carcinoma, SCC ¼¼öÈ«(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 10:19~10:37 8. Benign skin tumors ±èÈñÁÖ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 10:37~10:55 9. Alopecia and hair disorder À¯¹Ú¸°(°æÈñÀÇ´ë)
Åä·Ð 10-16 Vivace 10:55~11:00 10. Q&A ()
±³À°½Ã°£ 10-16 Allegro 08:00~08:20 1. Connective disease and bullous disease Áø¼±ÇÊ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-16 Allegro 08:20~08:40 2. Pigmentary, endocrine and metabolic disease ±Ç¼øÈ¿(°æÈñÀÇ´ë)
±³À°½Ã°£ 10-16 Allegro 08:40~09:05 3. Urticaria, erythematous and vascular disease ±è´ëÇö(°í·ÁÀÇ´ë)
ÈÞ½Ä 10-16 Allegro 09:05~09:10 Break ()
±³À°½Ã°£ 10-16 Allegro 09:10~09:30 4. Benign and malignant tumor of epidermis ÇÏ´ë·æ(°æºÏÀÇ´ë)
±³À°½Ã°£ 10-16 Allegro 09:30~09:50 5. Appendageal tumor, melanocytic tumor, tumor of dermis & Subcutaneous fat, lymphoma ¹éÀ¯»ó(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10-16 Allegro 09:50~10:10 6. Dermatitis due to physical forces, diseases of subcutaneous fat ¹Ú»óÇö(Àü³²ÀÇ´ë)
ÈÞ½Ä 10-16 Allegro 10:10~10:15 Break ()
±³À°½Ã°£ 10-16 Allegro 10:15~10:40 7. Laser and cosmetic dermatology ±èÁ¤Àº(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10-16 Allegro 10:40~11:00 8. Dermatosurgery ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë)
±âŸ 10-16 Harmony 1+2 11:10~11:13 1. Introduction Chair()
±³À°½Ã°£ 10-16 Harmony 1+2 11:13~11:58 2. Embracing the Potential of IL-17 inhibitor, from Psoriasis to HS Dr. Laura Savage(Leeds Teaching Hospitals NHS Trust UK)
Åä·Ð 10-16 Harmony 1+2 11:58~12:10 3. Q&A ()
±âŸ 10-16 Harmony 1+2 12:30~12:35 1. Introduction ()
±³À°½Ã°£ 10-16 Harmony 1+2 12:35~12:55 2. The relationship between air pollution and incidence of atopic dermatitis ¼Çö¹Î(ÇѾçÀÇ´ë)
Åä·Ð 10-16 Harmony 1+2 12:55~13:00 3. Q&A ()
±âŸ 10-16 Harmony 1+2 13:00~13:05 1. Introduction ()
±³À°½Ã°£ 10-16 Harmony 1+2 13:05~13:25 2. Cutaneous malassezia: Commensal, pathogen, or protector? ±èÁ¤Àº(°¡Å縯ÀÇ´ë)
Åä·Ð 10-16 Harmony 1+2 13:25~13:30 3. Q&A ()
±³À°½Ã°£ 10-16 Vivace 12:30~12:47 1. Micropunch grafting to complete vitiligo treatment ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú)
±³À°½Ã°£ 10-16 Vivace 12:47~13:04 2. Hairline correction surgery using follicular unit extraction ±è´ë¿ì(¸ð°ÇÇǺΰú)
±³À°½Ã°£ 10-16 Vivace 13:04~13:21 3. Perfect transconjunctival fat removal without recurrence and bleeding ±èº´Ã¶(¿¤·¹¸àÆ®ÇǺΰú)
Åä·Ð 10-16 Vivace 13:21~13:30 4. Q&A ()
±³À°½Ã°£ 10-16 Vivace 13:30~13:43 1. Cryotherapy for skin tumors ±èÁØ¿µ(°æºÏÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 13:43~13:56 2. Cryotherapy for inflammatory skin diseases ±èÇý¿ø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-16 Vivace 13:56~14:09 3. Cryotherapy for cosmetic purpose: Cryolipolysis °½ÂÈñ(¸®´õ½ºÇǺΰú)
±³À°½Ã°£ 10-16 Vivace 14:09~14:22 4. Basics of cooling and cryotherapy: Prevention and management of adverse effects ÀÌÁ¾Èñ(¼º±Õ°üÀÇ´ë)
Åä·Ð 10-16 Vivace 14:22~14:30 5. Q&A ()
±âŸ 10-16 Allegro 12:30~12:33 1. Introduction Chair()
±³À°½Ã°£ 10-16 Allegro 12:33~13:03 2. A new era of Atopic dermatitis, What À̵¿ÈÆ(¼¿ïÀÇ´ë)
Åä·Ð 10-16 Allegro 13:03~13:10 3. Q&A ()
±âŸ 10-16 Allegro 13:10~13:13 1. Introduction Chair()
±³À°½Ã°£ 10-16 Allegro 13:13~13:43 2. Avodart; All time favorite in real world! ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë)
Åä·Ð 10-16 Allegro 13:43~13:50 3. Q&A ()
±âŸ 10-16 Allegro 13:50~13:53 1. Introduction Chair()
±³À°½Ã°£ 10-16 Allegro 13:53~14:23 2. Efficacy? And safety of trifarotene in patients with facial and truncal acne ÃÖÈÆ(Á¶¼±ÀÇ´ë)
Åä·Ð 10-16 Allegro 14:23~14:30 3. Q&A ()
±âŸ 10-16 Allegro 15:00~15:03 1. Introduction Chair()
±³À°½Ã°£ 10-16 Allegro 15:03~15:33 2. Cyclosporine management in dermatology ±èÁ¤Àº(ÇѾçÀÇ´ë)
Åä·Ð 10-16 Allegro 15:33~15:40 3. Q&A ()
±âŸ 10-16 Allegro 15:40~15:43 1. Introduction Chair()
±³À°½Ã°£ 10-16 Allegro 15:43~16:13 2. A retrospective analysis of the factors affecting the treatment outcomes of cyclosporine ÀÌ°¡¿µ(¼º±Õ°üÀÇ´ë)
Åä·Ð 10-16 Allegro 16:13~16:20 3. Q&A ()
±³À°½Ã°£ 10-16 Allegro 16:20~16:23 1. Introduction Chair()
±³À°½Ã°£ 10-16 Allegro 16:23~16:53 2. DMF, a new oral treatment for moderate-to-severe psoriasis ¹æöȯ(°¡Å縯ÀÇ´ë)
Åä·Ð 10-16 Allegro 16:53~17:00 3. Q&A ()
±³À°½Ã°£ 10-16 Harmony 1+2 13:30~14:20 1. My experience of superficial and subcutaneous mycoses in Gyeongju for 31 years ¼¹«±Ô(µ¿±¹ÀÇ´ë)
Åä·Ð 10-16 Harmony 1+2 14:20~14:30 2. Q&A ()
±³À°½Ã°£ 10-16 Harmony 1+2 15:00~15:17 1. Bullous disease ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 1+2 15:17~15:34 2. Chronic urticaria ÃÖÁ¾¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-16 Harmony 1+2 15:34~15:51 3. Vitiligo À̽ÃÇü(¼¿ïÀÇ´ë)
Åä·Ð 10-16 Harmony 1+2 15:51~16:00 4. Q&A ()
±âŸ 10-16 Harmony 1+2 16:00~16:05 1. Introduction Chair()
±³À°½Ã°£ 10-16 Harmony 1+2 16:05~16:50 2. Dante, Puccini and their beloved Florence (featuring Bologna Medical School) À¯Á¤¿ì(Ȳ¼ºÁÖÅÐÅÐÇÑÇǺΰúÀÇ¿ø)
Åä·Ð 10-16 Harmony 1+2 16:50~17:00 3. Q&A ()
±âŸ 10-16 Vivace 15:00~15:05 1. Introduction Chair()
±³À°½Ã°£ 10-16 Vivace 15:05~15:29 2. Pigment lesion, dermatologist can treat differently ¾ÈÀμö(¹Ì¼Ò°¡ÀÎÇǺΰú)
±³À°½Ã°£ 10-16 Vivace 15:29~15:53 3. How can we treat acne (non-pharmacologic treatment) ¹æÂùÀÏ(ÈÞ¸ÕÇǺΰú)
±³À°½Ã°£ 10-16 Vivace 15:53~16:17 4. [Skin tightening, Lifting, Contouring, Wrinkles, +¥á] The skills to create opportunities Á¤¿î°æ(À¯¾ØÁ¤ÇǺΰú)
±³À°½Ã°£ 10-16 Vivace 16:17~16:41 5. The importance of dermocosmetics and its role in dermatological treatment ÀÌÇÏÀº(Æ÷·¹ÇǺΰú)
Åä·Ð 10-16 Vivace 16:41~17:00 6. Q&A ()